The PDF version of the letter has all tables and footnotes: KEI-NIH-28Aug2028 August 28, 2024 Abby Rives, JD Division Director Technology Transfer and Innovation Policy National Institutes for Health Vladimir Knezevic, MD Senior Advisor for Commercial Evaluation Technology Advancement Office… Continue Reading
2016-Mar25-email-Re-Dir-Sig-Response-March-In-Letter 2016-Dec18-Email-Chain-Re-Reasonable-Pricing-Clauses 2016-Dec24-Email-Seeking-Help-Re-NCI-Criticism-Response 2016-Dec25-Email-Seeking-Help-NCI-Rebuttal 2016Mar30-Email-Sen-Sanders-Letter 2016Apr26-Email-Nader-Response 2016Jun27-Email-re-March-in Process 2017-Jan3-Email-Re-Help-NCI-Rebuttal 2017Jan5-Email-Regarding-Kite-License-Applicants 2017Apr24-Email-Chain-Re-Xtandi-Appeal 2017Nov20-email-helping-Allen 2017-Dec7-Email-Re-Placing-Op-Ed 2019Apr16-email-CAR T-information
On Friday April 17, 2020, Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) regarding the “Prospective Grant of an Exclusive Patent License: Methods and Compositions for Adoptive Cell Therapy” to Lyell Immunopharma, Inc. (85 FR… Continue Reading
Today, the Office of the United States Trade Representative hosted the hearing for the annual Special 301 Review. The review process includes a solicitation of written comments and hearing testimony, and results in the publication of the Special 301 Report.… Continue Reading
On Tuesday, 1 October 2019, Knowledge Ecology International delivered the following opening statement at the 2019 WIPO General Assembly. Thank you Chair. KEI opposes any further work at the SCCR on a broadcast treaty, given the confusion over the objectives… Continue Reading
On Monday, 24 June 2019, Knowledge Ecology International (KEI) delivered this opening statement at WIPO’s 30th Session of the Standing Committee on the Law of Patents (SCP). The Committee elected a new chair, Sarah Whitehead, United Kingdom of Great Britain… Continue Reading
One of the reasons why drug companies have fought so hard to block transparency of clinical trial costs is the growing gap between what the public had been told those costs are, and the actual costs, particularly for treatments for… Continue Reading
On Wednesday May 22, 2019, KEI delivered the following intervention at the 72nd World Health Assembly for the agenda item, “11.5 – Universal Health Coverage.” A PDF version is available here. KEI Statement – WHA72 11.5 – Universal Health Coverage… Continue Reading
Perhaps the toughest issue in the 72nd World Health Assembly negotiations on a WHO transparency resolution concerns the proposal to require public reporting of the costs of each clinical trial undertaken for development of drugs, vaccines, cell- and gene-therapies and… Continue Reading
We now keep track of our FOIA requests here. Recent NIH FOIAs: https://www.keionline.org/foia/nih Older logs and pages about selected Freedom of Information Act (FOIA) requests filed by KEI. Centers for Disease Control and Prevention (CDC) March 3, 2015: CDC FOIA… Continue Reading